{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T20:46:43Z","timestamp":1776977203970,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012465","name":"Nemours Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012465","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016610","name":"Andrew McDonough B+ Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016935","name":"Lisa Dean Moseley Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016935","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.omtm.2020.09.007","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T12:11:44Z","timestamp":1600258304000},"page":"201-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Modeling Transient Abnormal Myelopoiesis Using Induced Pluripotent Stem Cells and CRISPR\/Cas9 Technology"],"prefix":"10.1016","volume":"19","author":[{"given":"Sonali P.","family":"Barwe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishnoor","family":"Sidhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Anders","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0465-578X","authenticated-orcid":false,"given":"Anilkumar","family":"Gopalakrishnapillai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2020.09.007_bib1","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.3324\/haematol.2010.024968","article-title":"Acute leukemia in children with Down syndrome","volume":"95","author":"Xavier","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.omtm.2020.09.007_bib2","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/blood-2008-11-163501","article-title":"Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome","volume":"113","author":"Malinge","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2020.09.007_bib3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s12185-016-1959-5","article-title":"Evolution of myeloid leukemia in children with Down syndrome","volume":"103","author":"Saida","year":"2016","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.omtm.2020.09.007_bib4","doi-asserted-by":"crossref","first-page":"6102","DOI":"10.1038\/onc.2010.351","article-title":"Trisomic dose of several chromosome 21 genes perturbs haematopoietic stem and progenitor cell differentiation in Down\u2019s syndrome","volume":"29","author":"De Vita","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.omtm.2020.09.007_bib5","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.celrep.2016.04.031","article-title":"Systematic Cellular Disease Models Reveal Synergistic Interaction of Trisomy 21 and GATA1 Mutations in Hematopoietic Abnormalities","volume":"15","author":"Banno","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtm.2020.09.007_bib6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/asheducation-2015.1.507","article-title":"Acute myeloid leukemia in children and adolescents: identification of new molecular targets brings promise of new therapies","volume":"2015","author":"Kolb","year":"2015","journal-title":"Hematology (Am. Soc. Hematol. Educ. Program)"},{"key":"10.1016\/j.omtm.2020.09.007_bib7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng955","article-title":"Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome","volume":"32","author":"Wechsler","year":"2002","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtm.2020.09.007_bib8","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/blood-2015-05-567859","article-title":"The biology of pediatric acute megakaryoblastic leukemia","volume":"126","author":"Gruber","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2020.09.007_bib9","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1182\/blood-2003-10-3383","article-title":"Natural history of GATA1 mutations in Down syndrome","volume":"103","author":"Ahmed","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2020.09.007_bib10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/pbc.20066","article-title":"GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia","volume":"44","author":"Crispino","year":"2005","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.omtm.2020.09.007_bib11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.bcmd.2003.08.001","article-title":"Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome","volume":"31","author":"Greene","year":"2003","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.omtm.2020.09.007_bib12","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1101\/gad.1903410","article-title":"Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis","volume":"24","author":"Klusmann","year":"2010","journal-title":"Genes Dev."},{"key":"10.1016\/j.omtm.2020.09.007_bib13","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/leu.2013.373","article-title":"GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia","volume":"28","author":"Maroz","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.omtm.2020.09.007_bib14","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1126\/science.1227682","article-title":"Medicine. iPSC disease modeling","volume":"338","author":"Soldner","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.omtm.2020.09.007_bib15","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s12185-012-1095-9","article-title":"Promise and challenges of human iPSC-based hematologic disease modeling and treatment","volume":"95","author":"Ye","year":"2012","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.omtm.2020.09.007_bib16","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.omtn.2017.04.009","article-title":"CRISPR\/Cas9-Directed Reassignment of the GATA1 Initiation Codon in K562 Cells to Recapitulate AML in Down Syndrome","volume":"7","author":"Bloh","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2020.09.007_bib17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2141.2004.04982.x","article-title":"Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down\u2019s syndrome, revealing PRAME as a specific discriminating marker","volume":"125","author":"McElwaine","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omtm.2020.09.007_bib18","doi-asserted-by":"crossref","first-page":"17573","DOI":"10.1073\/pnas.1211175109","article-title":"Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells","volume":"109","author":"Chou","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2020.09.007_bib19","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1172\/JCI75714","article-title":"Pluripotent stem cells reveal erythroid-specific activities of the GATA1 N-terminus","volume":"125","author":"Byrska-Bishop","year":"2015","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2020.09.007_bib20","doi-asserted-by":"crossref","first-page":"17567","DOI":"10.1073\/pnas.1215468109","article-title":"Altered hematopoiesis in trisomy 21 as revealed through in\u00a0vitro differentiation of isogenic human pluripotent cells","volume":"109","author":"Maclean","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2020.09.007_bib21","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1182\/blood-2008-05-157859","article-title":"Trisomy 21 enhances human fetal erythro-megakaryocytic development","volume":"112","author":"Chou","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2020.09.007_bib22","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1038\/srep06136","article-title":"Down syndrome-associated haematopoiesis abnormalities created by chromosome transfer and genome editing technologies","volume":"4","author":"Kazuki","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2020.09.007_bib23","doi-asserted-by":"crossref","first-page":"e55530","DOI":"10.1371\/journal.pone.0055530","article-title":"Generation of megakaryocytic progenitors from human embryonic stem cells in a feeder- and serum-free medium","volume":"8","author":"Pick","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2020.09.007_bib24","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0301-472X(03)00004-3","article-title":"Differential maturation of megakaryocyte progenitor cells from cord blood and mobilized peripheral blood","volume":"31","author":"Schipper","year":"2003","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.omtm.2020.09.007_bib25","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1177\/1947601911404223","article-title":"GATA Transcription Factors and Cancer","volume":"1","author":"Zheng","year":"2010","journal-title":"Genes Cancer"},{"key":"10.1016\/j.omtm.2020.09.007_bib26","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00335-002-4002-5","article-title":"Emerging links between initiation of translation and human diseases","volume":"13","author":"Kozak","year":"2002","journal-title":"Mamm. Genome"},{"key":"10.1016\/j.omtm.2020.09.007_bib27","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1002\/ajmg.a.36703","article-title":"A mutation in the Kozak sequence of GATA4 hampers translation in a family with atrial septal defects","volume":"164A","author":"Mohan","year":"2014","journal-title":"Am. J. Med. Genet. A."},{"key":"10.1016\/j.omtm.2020.09.007_bib28","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1046\/j.1365-2141.2003.04754.x","article-title":"Beta+45\u00a0G \u2192 C: a novel silent beta-thalassaemia mutation, the first in the Kozak sequence","volume":"124","author":"De Angioletti","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omtm.2020.09.007_bib29","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1182\/blood-2008-04-152967","article-title":"Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations","volume":"112","author":"Tunstall-Pedoe","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2020.09.007_bib30","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1182\/blood-2010-05-282426","article-title":"Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia","volume":"116","author":"Kanezaki","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2020.09.007_bib31","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1182\/blood-2016-09-687871","article-title":"The GATA factor revolution in hematology","volume":"129","author":"Katsumura","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2020.09.007_bib32","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/j.1365-2443.2009.01338.x","article-title":"Induction of hyperproliferative fetal megakaryopoiesis by an N-terminally truncated GATA1 mutant","volume":"14","author":"Shimizu","year":"2009","journal-title":"Genes Cells"},{"key":"10.1016\/j.omtm.2020.09.007_bib33","doi-asserted-by":"crossref","first-page":"e1000123","DOI":"10.1371\/journal.pbio.1000123","article-title":"Direct binding of pRb\/E2F-2 to GATA-1 regulates maturation and terminal cell division during erythropoiesis","volume":"7","author":"Kadri","year":"2009","journal-title":"PLoS Biol."},{"key":"10.1016\/j.omtm.2020.09.007_bib34","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood.2019001234","article-title":"Chromatin occupancy and epigenetic analysis reveal new insights into the function of the GATA1\u00a0N terminus in erythropoiesis","volume":"134","author":"Ling","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2020.09.007_bib35","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/ng.2759","article-title":"The landscape of somatic mutations in Down syndrome-related myeloid disorders","volume":"45","author":"Yoshida","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtm.2020.09.007_bib36","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2013-03-491936","article-title":"Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome","volume":"122","author":"Nikolaev","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2020.09.007_bib37","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ccell.2019.06.007","article-title":"Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome","volume":"36","author":"Labuhn","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omtm.2020.09.007_bib38","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1038\/ncomms5430","article-title":"Role of astroglia in Down\u2019s syndrome revealed by patient-derived human-induced pluripotent stem cells","volume":"5","author":"Chen","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2020.09.007_bib39","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.cell.2008.07.041","article-title":"Disease-specific induced pluripotent stem cells","volume":"134","author":"Park","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2020.09.007_bib40","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11033-006-0013-8","article-title":"Practical application of fluorescent quantitative PCR on Trisomy 21 in Chinese Han population","volume":"33","author":"Sun","year":"2006","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.omtm.2020.09.007_bib41","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"issue":"W1","key":"10.1016\/j.omtm.2020.09.007_bib42","doi-asserted-by":"crossref","first-page":"W242","DOI":"10.1093\/nar\/gky354","article-title":"CRISPOR: intuitive guide selection for CRISPR\/Cas9 genome editing experiments and screens","volume":"46","author":"Concordet","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtm.2020.09.007_bib43","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1093\/nar\/gku936","article-title":"Easy quantitative assessment of genome editing by sequence trace decomposition","volume":"42","author":"Brinkman","year":"2014","journal-title":"Nucleic Acids Res."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050120301923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050120301923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:23:18Z","timestamp":1762420998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050120301923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":43,"alternative-id":["S2329050120301923"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2020.09.007","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modeling Transient Abnormal Myelopoiesis Using Induced Pluripotent Stem Cells and CRISPR\/Cas9 Technology","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2020.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s).","name":"copyright","label":"Copyright"}]}}